Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg have identified a previously undocumented, organ-specific toxicity linked to CD19-targeted CAR T-cell therapy in autoimmune disease.

Verismo Therapeutics, a clinical-stage CAR T company pioneering the KIR-CAR platform, today provided additional details on ...